Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 7/20 | 0.63 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 5/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16614681 | 0.94 | F2RL1 (0.63) | F2RL1CFTRGRM5 | |
| SCHEMBL16614959 | 0.93 | F2RL1 (0.62) | F2RL1KMOCFTRGRM5 | |
| SCHEMBL16614660 | 0.92 | F2RL1 (0.62) | F2RL1KMOCFTRGRM5GRIN2B | |
| SCHEMBL16614736 | 0.91 | F2RL1 (0.76) | F2RL1CFTRGRM5 | |
| SCHEMBL16614910 | 0.90 | F2RL1 (0.62) | F2RL1KMOCFTRGRM5GRIN2B | |
| SCHEMBL16614641 | 0.90 | F2RL1 (0.65) | F2RL1CFTRGRM5TP53 | |
| SCHEMBL16614500 | 0.89 | F2RL1 (0.61) | F2RL1KMOCFTRRIPK1 | |
| SCHEMBL16614499 | 0.89 | F2RL1 (0.59) | F2RL1KMOCFTRGRM5GRIN2B | |
| SCHEMBL16614628 | 0.88 | F2RL1 (0.63) | F2RL1KMOCFTRGRM5GRIN2B | |
| SCHEMBL16614642 | 0.88 | F2RL1 (0.65) | F2RL1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED | 2019-04-25 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-10-27 | — | — | US | disclosed |
| WO-2015048245-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119282-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | F2RL1 1/4885KMO 974/4885CFTR 398/4885 |
| US-20160311825-A1 | IMIDAZOPYRIDAZINES USEFUL AS INHIBITORS OF THE PAR-2 SIGNALING PATHWAY | F2RL1, F2R, F2RL3 | F2RL1 1/4885KMO 974/4885CFTR 398/4885 |
| US-10030024-B2 | Imidazopyridazines useful as inhibitors of the PAR-2 signaling pathway | F2RL1, F2R, F2RL3 | F2RL1 1/4885KMO 974/4885CFTR 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.